PHI 31 Study Guide - Final Guide: Harmanpreet Kaur, Exenatide, Acute Pancreatitis
Document Summary
A study found no increased risk of acute pancreatitis with current or recent use of exenatide twice daily compared with use of other anti-diabetic drugs. This follow-up study investigated incident acute pancreatitis, with the use of a different data source and analytic method, in patients exposed to exenatide twice daily compared with patients exposed to other anti-diabetic medications. Of 482 034 eligible patients, 24 237 initiated exenatide twice daily and 457 797 initiated another anti-diabetic medication. Initiators of exenatide twice daily had more severe diabetes compared with initiators of other anti-diabetic medications. After adjustments for propensity score, insulin and use of medication potentially associated with acute pancreatitis, the odds ratio with exenatide twice daily exposure was 0. 95 (95% ci 0. 65 1. 38). A secondary analysis that examined current, recent and past medication exposure found no increased risk of acute pancreatitis with exenatide twice daily, regardless of exposure category. 6 step program: evaluation: real world population and causal hypothesis:
